GET DAILY SIGNALS60 Degrees Pharmaceuticals (SXTP) Q3 2026 Earnings Preview: Tracking Narrowing Losses
Key Takeaways
- 60 Degrees Pharmaceuticals is set to report third-quarter 2026 results on November 12, 2026, before the market opens, followed by a conference call on November 13.
- Wall Street consensus estimates a loss of about $0.61 per share on revenue near $270,000.
- This marks progress from the year-ago third-quarter loss of roughly $2.64 per share, continuing the recent pattern of steadily smaller quarterly losses.
- In Q2 2026, the company reported EPS of -$0.90, missing the -$0.74 consensus, while revenue of $207,900 edged above estimates.
- Investors will focus on ARAKODA (tafenoquine) sales trends, cash runway, and any updates regarding the babesiosis clinical program.
- For more context on this ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast on Tickeron.
- Additional ideas can be found by reviewing Trending AI Robots.
Earnings Context and Why It Matters
60 Degrees Pharmaceuticals, Inc. (SXTP) is a clinical-stage and commercial pharmaceutical company developing treatments for vector-borne diseases. Its lead product, ARAKODA (tafenoquine), targets malaria prevention, and the company is also advancing a tafenoquine-based program for babesiosis. As a micro-cap firm, quarterly results often move the stock noticeably. After achieving a 65% rise in fiscal 2025 net product revenue to around $1.0 million, management continues efforts to translate early commercial progress into a narrower loss profile. For investors, the focus here is less on near-term profits and more on whether revenue growth, spending discipline, and clinical advances can extend the cash runway as losses keep shrinking.
Earnings Expectations
Consensus ahead of the Q3 2026 release calls for a loss of roughly $0.61 per share and revenue of approximately $270,000. This would represent clear improvement from the prior-year quarter’s loss of about $2.64 per share. In the most recent quarter, Q2 2026, SXTP posted EPS of -$0.90, missing the -$0.74 consensus, while revenue of $207,900 came in modestly above the $185,000–$205,000 range. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The company has beaten consensus EPS estimates in only two of the last eight quarters, which warrants some caution. Without formal quarterly guidance, investors lean on consensus figures and management commentary. Key items to watch include ARAKODA sales, gross margins, trends in R&D and selling expenses, and the cash position at quarter-end.
Market Reaction and Investor Sentiment
Sentiment ahead of the report stays measured. SXTP is a thinly traded, higher-beta micro-cap with notable share-price volatility over the past year, and the narrowing loss trend has not yet built lasting investor confidence. With limited analyst coverage and a “Hold” average rating, expectations remain modest.
Primary risks center on cash runway management, possible additional equity raises via the at-the-market facility, and the uncertainty typical of early-stage clinical work. Positive remarks on ARAKODA demand or babesiosis trial timelines could support the shares, while signs of faster cash burn or delayed milestones might weigh on the stock given its liquidity profile.
Forward Outlook and Key Factors to Monitor
After the Q3 2026 report, several forward-looking elements stand out. The clinical pipeline remains the main long-term driver. Management has noted that an interim analysis of the randomized hospital study in babesiosis could arrive as early as late in the third quarter if 2026 tick-season recruitment follows 2025 patterns. Any update on that schedule will draw attention.
Commercial execution is also important. Partnerships with GoodRx and Runway Health aim to broaden ARAKODA’s reach, so commentary on prescription trends and revenue conversion will help gauge whether top-line growth can sustain. Expense control and cash management matter greatly for a company of this scale; signs of disciplined operating costs alongside narrower losses would be encouraging.
Financing considerations remain relevant as well. The company has used its ATM facility before, and any signal of future dilution could pressure the share price. Balancing clinical, commercial, and capital factors will shape how the market views the quarter and the path into 2027.
Integrating AI Tools Into My Routine
In my own work, I turn to Tickeron’s AI Trading Bots to test how automated strategies might respond to earnings-driven volatility in names like SXTP. The platform lets me review historical patterns and risk parameters quickly, which helps frame expectations without replacing fundamental analysis. This approach keeps my process efficient while staying grounded in the data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SXTP sees MACD Histogram just turned negative
SXTP saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 06, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 21 instances where the indicator turned negative. In 19 of the 21 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SXTP as a result. In 46 of 52 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
SXTP moved below its 50-day moving average on November 04, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SXTP crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SXTP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SXTP entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +28.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where SXTP advanced for three days, in 100 of 122 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SXTP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.301) is normal, around the industry mean (3.498). P/E Ratio (-0.223) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.320) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. SXTP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SXTP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement